May 19, 2022 7:30 am EDT MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
May 16, 2022 7:30 am EDT MindMed Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 7:30 am EDT MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
May 11, 2022 7:30 am EDT MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
May 9, 2022 7:30 am EDT MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update